Dr. Alexander Bondoc · Hepatoblastoma-The Evolution of Biology, Surgery, and Transplantation
Follow
Article1 min read·Published Dec 2018Older

Hepatoblastoma-The Evolution of Biology, Surgery, and Transplantation

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Dec 2018 · 1 min read

In brief

In brief

Comprehensive review of hepatoblastoma management covering molecular pathogenesis, risk stratification, and multimodal treatment approaches. Emphasizes surgical principles and the evolving role of liver transplantation in achieving >90% disease-free survival in favorable-risk patients, contextualized within the AHEP-1531 international study framework.

Written by the GCMD Library team from the article.

Alexander Bondoc

The most common primary malignant liver tumor of childhood, hepatoblastoma has increased in incidence over the last 30 years, but little is still known about its pathogenesis. Discoveries in molecular biology provide clues but have yet to define targeted therapies. Disease-free survival varies according to stage, but is greater than 90% in favorable risk populations, in part due to improvements in chemotherapeutic regimens, surgical resection, and earlier referral to liver transplant centers. This article aims to highlight the principles of disease that guide current treatment algorithms. Surgical treatment, especially orthotopic liver transplantation, will also be emphasized in the context of the current Children's Oncology Group international study of pediatric liver cancer (AHEP-1531).

Statements in this article

  1. Hepatoblastoma is the most common primary malignant liver tumor of childhood.

    Established
  2. The incidence of hepatoblastoma has increased over the last 30 years.

    Established
  3. Little is still known about the pathogenesis of hepatoblastoma.

    Open
  4. Discoveries in molecular biology provide clues but have yet to define targeted therapies for hepatoblastoma.

    Open
  5. Disease-free survival in hepatoblastoma varies according to stage.

    Established
  6. Disease-free survival is greater than 90% in favorable risk hepatoblastoma populations.

    Research
  7. Improved disease-free survival in hepatoblastoma is due in part to improvements in chemotherapeutic regimens, surgical resection, and earlier referral to liver transplant centers.

    Established

Read it at the source ↗

Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.